NASDAQ:CCCC C4 Therapeutics (CCCC) Stock Price, News & Analysis → The Small Biotech with a BIG Cancer Solution (From Behind the Markets) (Ad) Free CCCC Stock Alerts $8.05 +0.11 (+1.39%) (As of 03/27/2024 ET) Add Compare Share Share Today's Range$7.76▼$8.1450-Day Range$5.30▼$11.0052-Week Range$1.06▼$11.88Volume1.74 million shsAverage Volume4.36 million shsMarket Capitalization$552.24 millionP/E RatioN/ADividend YieldN/APrice Target$10.25 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get C4 Therapeutics alerts: Email Address C4 Therapeutics MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.50 Rating ScoreUpside/Downside27.3% Upside$10.25 Price TargetShort InterestBearish7.71% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.48Based on 2 Articles This WeekInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($1.86) to ($2.07) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.01 out of 5 starsMedical Sector813th out of 939 stocksBiological Products, Except Diagnostic Industry137th out of 154 stocks 3.3 Analyst's Opinion Consensus RatingC4 Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 3 buy ratings, 3 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $10.25, C4 Therapeutics has a forecasted upside of 27.3% from its current price of $8.05.Amount of Analyst CoverageC4 Therapeutics has only been the subject of 3 research reports in the past 90 days. Previous Next 2.0 Short Interest Percentage of Shares Shorted7.71% of the outstanding shares of C4 Therapeutics have been sold short.Short Interest Ratio / Days to CoverC4 Therapeutics has a short interest ratio ("days to cover") of 1.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in C4 Therapeutics has recently increased by 78.11%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldC4 Therapeutics does not currently pay a dividend.Dividend GrowthC4 Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for CCCC. Previous Next 1.4 News and Social Media Coverage News SentimentC4 Therapeutics has a news sentiment score of 0.48. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.61 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for C4 Therapeutics this week, compared to 2 articles on an average week.Search InterestOnly 20 people have searched for CCCC on MarketBeat in the last 30 days. This is a decrease of -63% compared to the previous 30 days.MarketBeat FollowsOnly 7 people have added C4 Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -30% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, C4 Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 7.97% of the stock of C4 Therapeutics is held by insiders.Percentage Held by Institutions78.81% of the stock of C4 Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for C4 Therapeutics are expected to decrease in the coming year, from ($1.86) to ($2.07) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of C4 Therapeutics is -3.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of C4 Therapeutics is -3.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioC4 Therapeutics has a P/B Ratio of 1.98. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Crypto 101 MediaMajor Elon Musk Crypto Leak RevealedReports of a leaked meeting between Elon Musk and staff at X.com could send shockwaves through the crypto market. Musk revealed a "mind-blowing" plan to take over the global payment system. In his own words, the world's richest man said "you won't need a bank account." Prominent voices in crypto believe what comes next will mirror a crypto mass adoption similar to the one that triggered bitcoin's last bull run.Click here now to get your copy. About C4 Therapeutics Stock (NASDAQ:CCCC)C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting IKZF1 and IKZF3 for multiple myeloma and non-Hodgkin lymphomas, including peripheral T-cell lymphoma and mantle cell lymphoma, currently under Phase 1/2 clinical trials. The company is also developing CFT1946, an orally bioavailable BiDAC degrader targeting V600X mutant BRAF to treat melanoma, non-small cell lung cancer (NSCLC), colorectal cancer, and other solid malignancies, currently under Phase 1/2 clinical trials; and CFT8919, an orally bioavailable, allosteric, and mutant-selective BiDAC degrader of epidermal growth factor receptor, or EGFR, with an L858R mutation in NSCLC. It has strategic collaborations with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; Biogen MA, Inc.; Betta Pharmaceuticals, Co., Ltd.; and Merck Sharp & Dohme, LLC, as well as Calico Life Sciences LLC. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.Read More CCCC Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CCCC Stock News HeadlinesMarch 28, 2024 | finance.yahoo.comHere’s Why Meridian Small Cap Growth Fund Trimmed C4 Therapeutics (CCCC)March 20, 2024 | americanbankingnews.comC4 Therapeutics, Inc. (NASDAQ:CCCC) Given Consensus Recommendation of "Moderate Buy" by BrokeragesMarch 28, 2024 | Gold Safe Exchange (Ad)Trump’s “Tax Free” Retirement Strategy Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.March 16, 2024 | finance.yahoo.comCCCC Mar 2024 17.000 callMarch 16, 2024 | finance.yahoo.comCCCC Mar 2024 10.000 putMarch 9, 2024 | nasdaq.comGuru Fundamental Report for CCCCMarch 5, 2024 | globenewswire.comC4 Therapeutics to Present New Preclinical Data on Highly Selective Orally Bioavailable BiDAC™ Degraders at the American Association for Cancer Research Annual Meeting 2024March 4, 2024 | globenewswire.comC4 Therapeutics Announces Strategic Discovery Research Collaboration with Merck KGaA, Darmstadt, Germany, Against Critical Oncogenic ProteinsMarch 28, 2024 | Crypto 101 Media (Ad)Altcoin FRENZY Alert…Bitcoin recently crossed the highest price in its 15-year history… Less than 2 years after one of the most vicious crypto market meltdowns we've ever seen! Bitcoin's BOOM also sent shockwaves through the altcoin market, with select coins seeing HUGE moves in a matter of days… Like Fetch.ai, that gained over 350% in just the last 30 days… March 2, 2024 | finance.yahoo.comCCCC Mar 2024 9.000 callMarch 1, 2024 | seekingalpha.comC4 Therapeutics' TORPEDO Platform Is Promising, But Its Valuation Remains StretchedFebruary 27, 2024 | finance.yahoo.comNew Forecasts: Here's What Analysts Think The Future Holds For C4 Therapeutics, Inc. (NASDAQ:CCCC)February 26, 2024 | markets.businessinsider.comBreaking Down C4 Therapeutics: 4 Analysts Share Their ViewsFebruary 25, 2024 | finance.yahoo.comCCCC Mar 2024 8.500 putFebruary 24, 2024 | ca.finance.yahoo.comCCCC Mar 2024 7.000 putFebruary 24, 2024 | finance.yahoo.comC4 Therapeutics Full Year 2023 Earnings: Misses ExpectationsFebruary 23, 2024 | markets.businessinsider.comStrong Financials and Promising Drug Pipeline Bolster Buy Rating for C4 TherapeuticsFebruary 23, 2024 | realmoney.thestreet.comC4 Therapeutics price target raised by $1 at Stifel, here's whyFebruary 22, 2024 | benzinga.comC4 Therapeutics Stock (NASDAQ:CCCC) Insider TradesFebruary 22, 2024 | finanznachrichten.deC4 Therapeutics, Inc.: C4 Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business HighlightsFebruary 22, 2024 | finance.yahoo.comC4 Therapeutics Inc (CCCC) Reports Full Year 2023 Financial Results and Business UpdatesFebruary 22, 2024 | finance.yahoo.comC4 Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business HighlightsFebruary 22, 2024 | globenewswire.comC4 Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business HighlightsFebruary 17, 2024 | finance.yahoo.comCCCC Feb 2024 9.000 putFebruary 15, 2024 | finance.yahoo.comC4 Therapeutics, Inc. (CCCC) May Report Negative Earnings: Know the Trend Ahead of Q4 ReleaseFebruary 15, 2024 | finance.yahoo.comC4 Therapeutics (CCCC) to Report Q4 Earnings: What's in Store?February 13, 2024 | finance.yahoo.comCCCC Feb 2024 4.500 putSee More Headlines Receive CCCC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for C4 Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/22/2024Today3/27/2024Next Earnings (Estimated)5/02/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:CCCC CUSIPN/A CIK1662579 Webwww.c4therapeutics.com Phone617-231-0700FaxN/AEmployees145Year FoundedN/APrice Target and Rating Average Stock Price Target$10.25 High Stock Price Target$20.00 Low Stock Price Target$2.00 Potential Upside/Downside+27.3%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)($2.67) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-132,490,000.00 Net Margins-638.34% Pretax Margin-632.17% Return on Equity-55.30% Return on Assets-35.80% Debt Debt-to-Equity RatioN/A Current Ratio6.34 Quick Ratio6.34 Sales & Book Value Annual Sales$20.76 million Price / Sales26.60 Cash FlowN/A Price / Cash FlowN/A Book Value$4.07 per share Price / Book1.98Miscellaneous Outstanding Shares68,600,000Free Float63,134,000Market Cap$552.23 million OptionableOptionable Beta3.24 Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report Key ExecutivesMr. Andrew J. Hirsch M.B.A. (Age 53)CEO, President & Director Comp: $971kDr. Kenneth C. Anderson M.D. (Age 73)Ph.D., Co-Founder, Independent Director & Member of Scientific Advisory Board Comp: $39.03kDr. Stewart Fisher (Age 57)Chief Scientific Officer Comp: $657.34kMr. Scott N. Boyle M.B.A. (Age 46)Ph.D., Chief Business Officer Comp: $672.78kDr. Nathanael S. Gray Ph.D.Co-Founder & Member of Scientific Advisory BoardMs. Kendra AdamsChief Financial OfficerMr. Mark Mossler (Age 51)Chief Accounting Officer Ms. Jolie M. Siegel J.D. (Age 47)Chief Legal Officer & Corporate Secretary Comp: $610.4kMs. Kelly A. Schick (Age 44)Chief People Officer Dr. Isabel Chiu Ph.D.Senior Vice President of Strategic Alliances & Business DevelopmentMore ExecutivesKey CompetitorsValnevaNASDAQ:VALNAlectorNASDAQ:ALECTaysha Gene TherapiesNASDAQ:TSHASolid BiosciencesNASDAQ:SLDBEditas MedicineNASDAQ:EDITView All CompetitorsInstitutional OwnershipVanguard Group Inc.Bought 74,545 shares on 3/11/2024Ownership: 2.915%Goldman Sachs Group Inc.Sold 105,210 shares on 3/1/2024Ownership: 0.230%Price T Rowe Associates Inc. MDBought 372,021 shares on 2/16/2024Ownership: 5.192%Bridgeway Capital Management LLCSold 25,000 shares on 2/15/2024Ownership: 0.252%Prelude Capital Management LLCSold 33,400 shares on 2/15/2024Ownership: 0.036%View All Institutional Transactions CCCC Stock Analysis - Frequently Asked Questions Should I buy or sell C4 Therapeutics stock right now? 6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for C4 Therapeutics in the last twelve months. There are currently 3 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" CCCC shares. View CCCC analyst ratings or view top-rated stocks. What is C4 Therapeutics' stock price target for 2024? 6 equities research analysts have issued 12 month price targets for C4 Therapeutics' shares. Their CCCC share price targets range from $2.00 to $20.00. On average, they anticipate the company's stock price to reach $10.25 in the next year. This suggests a possible upside of 27.3% from the stock's current price. View analysts price targets for CCCC or view top-rated stocks among Wall Street analysts. How have CCCC shares performed in 2024? C4 Therapeutics' stock was trading at $5.65 at the beginning of 2024. Since then, CCCC shares have increased by 42.5% and is now trading at $8.05. View the best growth stocks for 2024 here. Are investors shorting C4 Therapeutics? C4 Therapeutics saw a increase in short interest during the month of March. As of March 15th, there was short interest totaling 5,290,000 shares, an increase of 78.1% from the February 29th total of 2,970,000 shares. Based on an average daily volume of 4,830,000 shares, the short-interest ratio is presently 1.1 days. View C4 Therapeutics' Short Interest. When is C4 Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024. View our CCCC earnings forecast. How were C4 Therapeutics' earnings last quarter? C4 Therapeutics, Inc. (NASDAQ:CCCC) posted its quarterly earnings data on Thursday, February, 22nd. The company reported ($0.68) EPS for the quarter, missing analysts' consensus estimates of ($0.67) by $0.01. The firm earned $3.26 million during the quarter, compared to analyst estimates of $5.23 million. C4 Therapeutics had a negative trailing twelve-month return on equity of 55.30% and a negative net margin of 638.34%. When did C4 Therapeutics IPO? C4 Therapeutics (CCCC) raised $150 million in an IPO on Friday, October 2nd 2020. The company issued 8,800,000 shares at a price of $16.00-$18.00 per share. Jefferies, Evercore ISI, BMO Capital Markets and UBS Investment Bank acted as the underwriters for the IPO. Who are C4 Therapeutics' major shareholders? C4 Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Wasatch Advisors LP (14.49%), Commodore Capital LP (7.71%), Price T Rowe Associates Inc. MD (5.19%), Price T Rowe Associates Inc. MD (5.19%), Vanguard Group Inc. (4.06%) and Vanguard Group Inc. (2.91%). Insiders that own company stock include Adam Crystal, Andrew Hirsch, Elena Prokupets, Jolie Siegel, Malcolm Salter, Stewart Fisher and Utpal Koppikar. View institutional ownership trends. How do I buy shares of C4 Therapeutics? Shares of CCCC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:CCCC) was last updated on 3/28/2024 by MarketBeat.com Staff From Our PartnersTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeTop Project Outperforms BTC in 2023…Crypto 101 MediaMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading AcademyBREAKING: New AI Breakthrough Could Change Healthcare ForeverBehind the Markets“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisorySHOCKING Footage From Tesla Gigafactory In Austin, TexasInvestorPlaceBuy this small stock before coming AI Tidal WaveChaikin Analytics Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding C4 Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.